• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Directories » FDA Approved Drugs » Sivextro (tedizolid phosphate)

AND
  • A
  • B
  • C
  • D
  • E
  • F
  • G
  • H
  • I
  • J
  • K
  • L
  • M
  • N
  • O
  • P
  • Q
  • R
  • S
  • T
  • U
  • V
  • W
  • X
  • Y
  • Z

Sivextro (tedizolid phosphate)

  • Profile

Profile

Contact Information

Contact: Merck Sharp & Dohme Corp.
Website: http://www.sivextro.com/dosing-administration/

Currently Enrolling Trials

    Show More

    General Information

    Sivextro (tedizolid phosphate) is an antibacterial agent of the oxazolidinone class.

    Sivextro is specifically indicated for the treatment of adults with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible isolates of the following Gram-positive microorganisms: Staphylococcus aureus (including methicillin-resistant [MRSA] and methicillin-susceptible [MSSA] isolates), Streptococcus pyogenes, Streptococcus agalactiae, Streptococcus anginosus Group (including Streptococcus inosus, Streptococcus intermedius, and Streptococcus constellatus), and Enterococcus faecalis.

    Mechanism of Action

    Sivextro (tedizolid phosphate) is an antibacterial agent of the oxazolidinone class. The antibacterial activity of tedizolid is mediated by binding to the 50S subunit of the bacterial ribosome resulting in inhibition of protein synthesis. Tedizolid inhibits bacterial protein synthesis through a mechanism of action different from that of other non-oxazolidinone class antibacterial drugs; therefore, cross-resistance between tedizolid and other classes of antibacterial drugs is unlikely. The results of in vitro time-kill studies show that tedizolid is bacteriostatic against enterococci, staphylococci and streptococci.

    Side Effects

    Adverse effects associated with the use of Sivextro may include, but are not limited to, the following:

    • nausea
    • headache
    • diarrhea
    • vomiting
    • dizziness

    Dosing/Administration

    Sivextro is supplied as a tablet or solution, for oral and/or intravenous administration. The recommended dosage of Sivextro is 200 mg administered once daily for six days either orally (with or without food) or as an intravenous (IV) infusion.

    Clinical Trial Results

    The FDA approval of Sivextro was based on two multicenter, multinational, randomized, double-blind, non-inferiority trials. Both trials compared Sivextro 200 mg once daily for six days versus linezolid 600 mg every 12 hours for 10 days. In trial 1, subjects were treated with oral therapy, while in trial 2, subjects could receive oral therapy after a minimum of one day of intravenous therapy. Subjects with cellulitis/erysipelas, major cutaneous abscess or wound infection were enrolled in the trials. Subjects with wound infections could have received aztreonam and/or metronidazole as adjunctive therapy for gram-negative bacterial coverage, if needed. The intent-to-treat (ITT) patient population included all randomized patients. 

    Trial 1
    This trial randomized 323 subjects to Sivextro and 326 subjects to linezolid. The overall median surface area of infection was 190 cm2. The types of ABSSSI included were cellulitis/erysipelas (40 percent), wound infection (30 percent) and major cutaneous abscess (30 percent). In addition to local signs and symptoms of infection, subjects were required to have at least one regional or systemic sign of infection at baseline. The primary endpoint was early clinical response defined as no increase from baseline lesion area at 48-72 hours after the first dose and oral temperature of ≤37.6°C, confirmed by a second temperature measurement within 24 hours in the ITT population. The percentage of responders to the primary endpoint was 79.3 percent and 79.1 percent in the Sivextro and linezolid arms, respectively. 

    Trial 2
    This trial randomized 332 subjects to Sivextro and 334 subjects to linezolid. The overall median surface area of infection was 231 cm2. The types of ABSSSI included were cellulitis/erysipelas (50 percent), wound infection (30 percent) and major cutaneous abscess (20 percent). In addition to local signs and symptoms of infection, subjects were also required to have at least one regional or systemic sign of infection at baseline. The primary endpoint was early clinical response defined as at least a 20 percent decrease from baseline lesion area at 48-72 hours after the first dose in the ITT population. The percentage of responders to the primary endpoint was 85.2 percent and 82.6 percent in the Sivextro and linezolid arms, respectively. 

     

     

    Approval Date: 2014-06-01
    Company Name: Cubist Pharmaceuticals
    Back to Listings

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing